Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MAPK1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MAPK1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MAPK1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MAPK1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/MAPK1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/MAPK1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0000302110 | Oral cavity | LP | response to reactive oxygen species | 95/4623 | 222/18723 | 2.23e-09 | 9.98e-08 | 95 |
GO:190136116 | Oral cavity | LP | organic cyclic compound catabolic process | 180/4623 | 495/18723 | 3.11e-09 | 1.35e-07 | 180 |
GO:0031330110 | Oral cavity | LP | negative regulation of cellular catabolic process | 107/4623 | 262/18723 | 5.25e-09 | 2.16e-07 | 107 |
GO:000640219 | Oral cavity | LP | mRNA catabolic process | 97/4623 | 232/18723 | 6.51e-09 | 2.65e-07 | 97 |
GO:0042542110 | Oral cavity | LP | response to hydrogen peroxide | 68/4623 | 146/18723 | 6.95e-09 | 2.81e-07 | 68 |
GO:0062197110 | Oral cavity | LP | cellular response to chemical stress | 130/4623 | 337/18723 | 8.94e-09 | 3.52e-07 | 130 |
GO:004682218 | Oral cavity | LP | regulation of nucleocytoplasmic transport | 52/4623 | 106/18723 | 4.82e-08 | 1.67e-06 | 52 |
GO:0034599110 | Oral cavity | LP | cellular response to oxidative stress | 110/4623 | 288/18723 | 2.19e-07 | 6.65e-06 | 110 |
GO:000756819 | Oral cavity | LP | aging | 125/4623 | 339/18723 | 3.29e-07 | 9.62e-06 | 125 |
GO:004668513 | Oral cavity | LP | response to arsenic-containing substance | 22/4623 | 33/18723 | 4.25e-07 | 1.21e-05 | 22 |
GO:200037717 | Oral cavity | LP | regulation of reactive oxygen species metabolic process | 67/4623 | 157/18723 | 5.54e-07 | 1.51e-05 | 67 |
GO:001021216 | Oral cavity | LP | response to ionizing radiation | 64/4623 | 148/18723 | 5.60e-07 | 1.51e-05 | 64 |
GO:007121417 | Oral cavity | LP | cellular response to abiotic stimulus | 121/4623 | 331/18723 | 8.45e-07 | 2.20e-05 | 121 |
GO:010400417 | Oral cavity | LP | cellular response to environmental stimulus | 121/4623 | 331/18723 | 8.45e-07 | 2.20e-05 | 121 |
GO:004682415 | Oral cavity | LP | positive regulation of nucleocytoplasmic transport | 33/4623 | 62/18723 | 1.30e-06 | 3.16e-05 | 33 |
GO:000941112 | Oral cavity | LP | response to UV | 63/4623 | 149/18723 | 1.74e-06 | 4.05e-05 | 63 |
GO:000931417 | Oral cavity | LP | response to radiation | 155/4623 | 456/18723 | 4.12e-06 | 8.49e-05 | 155 |
GO:005117013 | Oral cavity | LP | import into nucleus | 65/4623 | 159/18723 | 4.78e-06 | 9.69e-05 | 65 |
GO:007147815 | Oral cavity | LP | cellular response to radiation | 73/4623 | 186/18723 | 7.44e-06 | 1.41e-04 | 73 |
GO:1903312110 | Oral cavity | LP | negative regulation of mRNA metabolic process | 42/4623 | 92/18723 | 9.38e-06 | 1.75e-04 | 42 |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
MAPK1 | CD8TEXINT | Colorectum | AD | ITGA1,YPEL1,UBASH3B, etc. | 2.57e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Colorectum/Str/TF_AD/regulons_activity_in_dotplot.png) |
MAPK1 | CD8TEREX | Colorectum | AD | ITGA1,YPEL1,UBASH3B, etc. | 2.43e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Colorectum/Str/TF_AD/regulons_activity_in_dotplot.png) |
MAPK1 | MAIT | Colorectum | ADJ | ITGA1,YPEL1,UBASH3B, etc. | 1.38e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Colorectum/Str/TF_ADJ/regulons_activity_in_dotplot.png) |
MAPK1 | CD8TEREX | Colorectum | ADJ | ITGA1,YPEL1,UBASH3B, etc. | 1.84e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Colorectum/Str/TF_ADJ/regulons_activity_in_dotplot.png) |
MAPK1 | CD8TEXINT | Colorectum | ADJ | ITGA1,YPEL1,UBASH3B, etc. | 1.00e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Colorectum/Str/TF_ADJ/regulons_activity_in_dotplot.png) |
MAPK1 | CD8TEREX | Colorectum | CRC | ITGA1,YPEL1,UBASH3B, etc. | 6.38e-02 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Colorectum/Str/TF_CRC/regulons_activity_in_dotplot.png) |
MAPK1 | TREG | Colorectum | CRC | ITGA1,YPEL1,UBASH3B, etc. | 1.20e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Colorectum/Str/TF_CRC/regulons_activity_in_dotplot.png) |
MAPK1 | TH17 | Colorectum | FAP | ITGA1,YPEL1,UBASH3B, etc. | 8.39e-02 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Colorectum/Str/TF_FAP/regulons_activity_in_dotplot.png) |
MAPK1 | CD8TEREX | Colorectum | FAP | ITGA1,YPEL1,UBASH3B, etc. | 2.37e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Colorectum/Str/TF_FAP/regulons_activity_in_dotplot.png) |
MAPK1 | MAIT | Colorectum | FAP | ITGA1,YPEL1,UBASH3B, etc. | 1.13e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Colorectum/Str/TF_FAP/regulons_activity_in_dotplot.png) |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAPK1 | SNV | Missense_Mutation | | c.241G>A | p.Glu81Lys | p.E81K | P28482 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-BH-A0B5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | CR |
MAPK1 | SNV | Missense_Mutation | rs747124623 | c.994G>A | p.Asp332Asn | p.D332N | P28482 | protein_coding | deleterious(0.03) | benign(0.001) | TCGA-E2-A14N-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
MAPK1 | insertion | Frame_Shift_Ins | novel | c.1024_1025insTTGTGAGCCAAGGTAGAAGCAGTTGCTGGGGAGATGC | p.Lys342IlefsTer20 | p.K342Ifs*20 | P28482 | protein_coding | | | TCGA-AN-A03Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAPK1 | SNV | Missense_Mutation | | c.964N>A | p.Glu322Lys | p.E322K | P28482 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-C5-A1BI-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
MAPK1 | SNV | Missense_Mutation | | c.964G>A | p.Glu322Lys | p.E322K | P28482 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD |
MAPK1 | SNV | Missense_Mutation | | c.961G>A | p.Asp321Asn | p.D321N | P28482 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-DG-A2KL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
MAPK1 | SNV | Missense_Mutation | | c.964N>A | p.Glu322Lys | p.E322K | P28482 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-DS-A0VN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
MAPK1 | SNV | Missense_Mutation | | c.964N>A | p.Glu322Lys | p.E322K | P28482 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-EA-A1QS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
MAPK1 | SNV | Missense_Mutation | | c.404G>A | p.Arg135Lys | p.R135K | P28482 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-EA-A3HT-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
MAPK1 | SNV | Missense_Mutation | | c.964G>A | p.Glu322Lys | p.E322K | P28482 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-EA-A5ZD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | PROGESTERONE | PROGESTERONE | |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | SPINASAPONIN A METHYL ESTER | SPINASAPONIN A METHYL ESTER | 20951582 |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | DIHYDROGAMBOGIC ACID | DIHYDROGAMBOGIC ACID | |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | TREQUINSIN HYDROCHLORIDE | TREQUINSIN HYDROCHLORIDE | |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | BENZOTHIAZOL-2-YLAMINE | CHEMBL329785 | 22982122 |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | PHENETHYLISOTHIOCYANATE | PHENETHYLISOTHIOCYANATE | 22607231 |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | GENTIAN VIOLET | GENTIAN VIOLET | |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | MITOXANTRONE DIHYDROCHLORIDE | MITOXANTRONE HYDROCHLORIDE | |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | DAUNORUBICIN HYDROCHLORIDE | DAUNORUBICIN HYDROCHLORIDE | |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | ZM-449829 | CHEMBL154580 | |